Clinical Trial Update: Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for cabozantinib in advanced pancreatic neuroendocrine tumors and carcinoid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Carcinoid Tumor, Pancreatic Neuroendocrine Tumor | Phase 2 | Status: COMPLETED | Results posted: 2023-07-20